Source:http://linkedlifedata.com/resource/pubmed/id/21495172
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2011-4-20
|
pubmed:abstractText |
The RASopathies, one of the largest groups of multiple congenital anomaly syndromes known, are caused by germline mutations in various genes encoding components of the Ras/mitogen-activated protein kinase (MAPK) pathway. The RASopathies have many overlapping characteristics, including craniofacial manifestations, cardiac malformations, cutaneous, musculoskeletal, gastrointestinal, and ocular abnormalities, neurocognitive impairment, hypotonia, and an increased risk of developing cancer. Costello syndrome (CS) and cardio-facio-cutaneous (CFC) syndrome are two of the more rare RASopathies. CS is caused by activating mutations in HRAS, and CFC is caused by dysregulation of signaling in the Ras/MAPK pathway due to mutations in BRAF, MEK1, or MEK2. The Ras/MAPK pathway, which has been well-studied in cancer, is an attractive target for inhibition in the treatment of various malignancies utilizing small molecule therapeutics that specifically inhibit the pathway. With many inhibitors of the Ras/MAPK pathway in clinical trials, the notion of using these molecules to ameliorate developmental defects in CS and CFC is under consideration. CS and CFC, like other syndromes in their class, have a progressive phenotype and may be amenable to inhibition or normalization of signaling.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Farnesyltranstransferase,
http://linkedlifedata.com/resource/pubmed/chemical/MAP Kinase Kinase 1,
http://linkedlifedata.com/resource/pubmed/chemical/MAP2K1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins p21(ras),
http://linkedlifedata.com/resource/pubmed/chemical/raf Kinases
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1552-4876
|
pubmed:author |
pubmed-author:BanerjeeAnuradhaA,
pubmed-author:BishopW RobertWR,
pubmed-author:LauchleJennifer OJO,
pubmed-author:McCormickFrankF,
pubmed-author:McMahonMartinM,
pubmed-author:MeleseTeriT,
pubmed-author:MunsterPamela NPN,
pubmed-author:NadafSorenaS,
pubmed-author:PackerRoger JRJ,
pubmed-author:RauenKatherine AKA,
pubmed-author:Sebolt-LeopoldJudithJ,
pubmed-author:ViskochilDavid HDH
|
pubmed:copyrightInfo |
2011 Wiley-Liss, Inc.
|
pubmed:issnType |
Electronic
|
pubmed:day |
15
|
pubmed:volume |
157
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
136-46
|
pubmed:meshHeading |
pubmed-meshheading:21495172-Clinical Trials as Topic,
pubmed-meshheading:21495172-Costello Syndrome,
pubmed-meshheading:21495172-Ectodermal Dysplasia,
pubmed-meshheading:21495172-Facies,
pubmed-meshheading:21495172-Failure to Thrive,
pubmed-meshheading:21495172-Farnesyltranstransferase,
pubmed-meshheading:21495172-Heart Defects, Congenital,
pubmed-meshheading:21495172-Humans,
pubmed-meshheading:21495172-MAP Kinase Kinase 1,
pubmed-meshheading:21495172-Neurofibromatosis 1,
pubmed-meshheading:21495172-Proto-Oncogene Proteins p21(ras),
pubmed-meshheading:21495172-Public-Private Sector Partnerships,
pubmed-meshheading:21495172-Research,
pubmed-meshheading:21495172-Signal Transduction,
pubmed-meshheading:21495172-raf Kinases
|
pubmed:year |
2011
|
pubmed:articleTitle |
Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies.
|
pubmed:affiliation |
Division of Medical Genetics at the University of California at San Francisco, USA. rauenk@peds.ucsf.edu
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|